What therapies are on the horizon for HER2 positive breast cancer?

References

• Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177–182.
   PubMed Web of Science ®Google Scholar
• Gabos Z, Sinha R, Hanson J, et al. Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J Clin Oncol. 2006;24:5658–5663.
   PubMed Web of Science ®Google Scholar
• Roth J, Bajaj P, Sullivan SD, et al. Survival gains from advances in first-line systemic therapy for HER2 overexpressing metastatic breast cancer in the U.S., 1995–2015. Abstract 263P, ESMO Congress 2017, Madrid, Spain.
   Google Scholar
• Gianni L, Pienkowski T, Im YH, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol. 2016;17:791–800.
   PubMed Web of Science ®Google Scholar
• Balic M, Thomssen C, Würstlein R, et al. St. Gallen/Vienna 2019: a brief summary of the consensus discussion on the optimal primary breast cancer treatment. Breast Care. 2019;14:103–110.
   PubMed Web of Science ®Google Scholar
• NCCN Clinical Practice. Guidelines in Oncology (NCCN Guidelines®) Version 1.2019. Mar 14, 2019.
   Google Scholar
• von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380:617–628.
   PubMed Web of Science ®Google Scholar
• Cameron D, Piccart-Gebhart MJ, Gelber RD, et al. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin adjuvant (HERA) trial. Lancet. 2017;389:1195–2105.
   PubMed Web of Science ®Google Scholar
• Esposito A, Viale G, Criscitiello C, et al. A clinical perspective on escalating or de-escalating adjuvant therapy in HER2+ breast cancer. Expert Rev Clin Pharmacol. 2019;12:9–16.
   PubMed Web of Science ®Google Scholar
• von Minckwitz G, Procter M, de Azambuja E, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med. 2017;377:122–131.
   PubMed Web of Science ®Google Scholar
• Chan A, Delaloge S, Holmes FA, et al. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2- positive breast cancer (ExteNET): a multicentre, randomised, double- blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2016;17:367–377.
   PubMed Web of Science ®Google Scholar
• Swain SM, Baselga J, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372:724–734.
   PubMed Web of Science ®Google Scholar
• Bachelot T, Ciruelos E, Schneeweiss A, et al. Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). Ann Oncol. 2019;30:766–773.
   PubMedGoogle Scholar
• Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367:1783–1791.
   PubMed Web of Science ®Google Scholar
• Diéras V, Miles D, Verma S, et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18:732–742.
   PubMed Web of Science ®Google Scholar
• Krop IE, Kim SB, Martin AG, et al. Trastuzumab emtansine versus treatment of physician’s choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. Lancet Oncol. 2017;18:743–754.
   PubMed Web of Science ®Google Scholar
• Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355:2733–2743.
   PubMed Web of Science ®Google Scholar
• Burstein HJ, Keshaviah A, Baron AD, et al. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer. 2007;110:965–972.
   PubMed Web of Science ®Google Scholar
• Arteaga CL, Sliwkowski MX, Osborne CK, et al. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol. 2011;9:16–32.
   PubMed Web of Science ®Google Scholar
• Puglisi F, Minisini AM, De Angelis C, et al. Overcoming treatment resistance in HER2-positive breast cancer: potential strategies. Drugs. 2012;72:1175–1193.
   PubMed Web of Science ®Google Scholar
• Hudis CA. Trastuzumab—mechanism of action and use in clinical practice. N Engl J Med. 2007;357:39–51.
   PubMed Web of Science ®Google Scholar
• Corrigan PA, Cicci TA, Auten JJ, et al. Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate. Ann Pharmacother. 2014;48:1484–1493.
   PubMed Web of Science ®Google Scholar
• Davis MI, Hunt JP, Herrgard S, et al. Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol. 2011;29:1046–1051.
   PubMed Web of Science ®Google Scholar
• Dolcetti R. Predictive value of FcR polymorphisms. A further step on the long and winding road to application. JAMA Oncol. 2017;3:342–343.
   PubMed Web of Science ®Google Scholar
• Nordstrom JL, Gorlatov S, Zhang W, et al. Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties. Breast Cancer Res. 2011;13:R123.
   PubMed Web of Science ®Google Scholar
• Bang YJ, Giaccone G, Im SA, et al. First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors. Ann Oncol. 2017;28:855–861.
   PubMed Web of Science ®Google Scholar
• Rugo HS, Im SA, Lynn G, et al. SOPHIA primary analysis: A phase 3 study of margetuximab+ chemotherapy versus trastuzumab + chemotherapy in patients with HER2+ metastatic breast cancer after prior anti-HER2 therapies. J Clin Oncol. 2019;37(15_suppl):abstr 1000.
   Google Scholar
• Freedman RA, Gelman RS, Anders CK, et al. TBCRC 022: a phase II trial of neratinib and capecitabine for patients with human epidermal growth factor receptor 2–positive breast cancer and brain metastases. J Clin Oncol. 2019;37:1081–1089.
   PubMed Web of Science ®Google Scholar
• Awada A, Colomer R, Inoue K, et al. Neratinib plus paclitaxel vs trastuzumab plus paclitaxel in previously untreated metastatic ERBB2-positive breast cancer: the NEfERT-T randomized clinical trial. JAMA Oncol. 2016;2:1557.
   PubMed Web of Science ®Google Scholar
• Barcenas CH, Ibrahim E, Wilkinson M. Incidence and severity of diarrhea with neratinib plus intensive loperamide prophylaxis in patients with HER2-positive early-stage breast cancer: interim analysis from the multicenter, open label, phase II CONTROL trial. Cancer Res. 2017;77(4 Supplement):P2-11-03.
   Google Scholar
• Saura C, Oliveira M, Feng Y-H, et al. Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: findings from the multinational, randomized, phase III NALA trial. J Clin Oncol. 2019;37(15_suppl):abstr 1002.
   Google Scholar
• Ma F, Li Q, Chen S, et al. Phase I study and biomarker analysis of pyrotinib, a novel irreversible Pan-ErbB receptor tyrosine kinase inhibitor, in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer. J Clin Oncol. 2017;35:3105–3112.
   PubMed Web of Science ®Google Scholar
• YH P, Lee K, Sohn J, et al. A Phase 2 study of poziotinib in patients with HER2-positive metastatic breast cancer (MBC) who have received prior HER2 regimens for MBC. Abstract 237O, ESMO 2017, Madrid, Spain
   Google Scholar
• Xu B, Ma F, Ouyang Q, et al. A randomized phase II trial of pyrotinib plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with taxanes, anthracyclines and/or trastuzumab. Cancer Res. 2018;78(4 Supplement):PD3–08.
   Web of Science ®Google Scholar
• Jiang Z, Yan M, Hu X, et al. Pyrotinib combined with capecitabine in women with HER2+ metastatic breast cancer previously treated with trastuzumab and taxanes: A randomized phase III study. J Clin Oncol. 2019;37(15_suppl):abstr 1001.
   Google Scholar
• Moulder SL, Borges VF, Baetz T, et al. Phase I study of ONT-380, a HER2 inhibitor, in patients with HER2+ – advanced solid tumors, with an expansion cohort in HER2+ metastatic breast cancer. Clin Cancer Res. 2017;23:3529–3536.
   PubMed Web of Science ®Google Scholar
• Anders C, Murthy R, Hamilton E, et al. A randomized, double-blinded, controlled study of tucatinib (ONT-380) vs. placebo in combination with capecitabine and trastuzumab in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (HER2CLIMB). Cancer Res. 2017;77:CT055.
   Web of Science ®Google Scholar
• Tolcher AW. Antibody drug conjugates: lessons from 20 years of clinical experience. Ann Oncol. 2016;27:2168–2172.
   PubMed Web of Science ®Google Scholar
• McCombs JR, Owen SC. Antibody drug conjugates: design and selection of linker, payload and conjugation chemistry. Aaps J. 2015;17:339–351.
   PubMed Web of Science ®Google Scholar
• Staudacher AH, Brown MP. Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required? Br J Cancer. 2017;117:1736–42.
   PubMed Web of Science ®Google Scholar
• Iwata H, Tamura K, Doi T, et al. Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing solid tumors: long-term results of a large phase 1 study with multiple expansion cohorts. J Clin Oncol. 2018;36:2501.
   Web of Science ®Google Scholar
• Tamura K, Tsurutani J, Takahashi S, et al. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study. Lancet Oncol. 2019;20:816–826.
   PubMed Web of Science ®Google Scholar
• Pondé N, Aftimos P, Piccart M. Antibody-drug conjugates in breast cancer: a comprehensive review. Curr Treat Options Oncol. 2019;20:37.
   PubMed Web of Science ®Google Scholar
• André F, Shahidi J, Lee C, et al. Trastuzumab deruxtecan (DS-8201a) vs investigator’s choice of treatment in subjects with HER2-positive, unresectable and/or metastatic breast cancer who previously received T-DM1: A randomized, phase 3 study. Cancer Res. 2019;79(4 Supplement):OT2-07-02.
   Web of Science ®Google Scholar
• van der Lee MMC, Groothuis PG, Ubink R, et al. The preclinical profile of the duocarmycin-based HER2-targeting ADC SYD985 predicts for clinical benefit in low HER2-expressing breast cancers. Mol Cancer Ther. 2015;14:692–703.
   PubMed Web of Science ®Google Scholar
• Aftimos PG, van Herpen CM, Mommers EC, et al. SYD985, a novel anti-HER2 ADC, shows promising activity in patients with HER2-positive and HER2-low metastatic breast cancer. Cancer Res. 2017;77(13 Supplement):P6-12-02.
   Google Scholar
• Miller K, Cortes J, Hurvitz SA, et al. HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician’s choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer. BMC Cancer. 2016;16:352.
   PubMed Web of Science ®Google Scholar
• Hamilton EP, Barve MA, Bardia A, et al. Phase 1 dose escalation of XMT-1522, a novel HER2-targeting antibody-drug conjugate (ADC), in patients with HER2-expressing breast, lung and gastric tumors. J Clin Oncol. 2018;36(15_suppl):2546.
   Web of Science ®Google Scholar
• Wang J, Xu B, Wang W, et al. An open-label, dose-escalation phase I study to evaluate RC48-ADC, a novel antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer. J Clin Oncol. 2018;36(15_suppl):1030.
   Web of Science ®Google Scholar
• Pegram M, Hamilton E, Tan AR, et al. Phase 1 study of bispecific HER2 antibody-drug conjugate MEDI4276 in patients with advanced HER2-positive breast or gastric cancer. Ann Oncol. 2018;29(suppl_3):iii7–iii9.
   Google Scholar
• Yi M, Jiao D, Xu H, et al. Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors. Mol Cancer. 2018;17:129.
   PubMed Web of Science ®Google Scholar
• Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379:2108–2121.
   PubMed Web of Science ®Google Scholar
• Luen SJ, Salgado R, Fox S, et al. Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study. Lancet Oncol. 2017;18:52–62.
   PubMed Web of Science ®Google Scholar
• Kim A, Lee SJ, Kim YK, et al. Programmed death-ligand 1 (PD-L1) expression in tumour cell and tumour infiltrating lymphocytes of HER2-positive breast cancer and its prognostic value. Sci Rep. 2017;7:11671.
   PubMed Web of Science ®Google Scholar
• Thomas A, Routh ED, Pullikuth A, et al. Tumor mutational burden is a determinant of immune-mediated survival in breast cancer. Oncoimmunology. 2018;e1490854.
   PubMed Web of Science ®Google Scholar
• Perez EA, Thompson EA, Ballman KV, et al. Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the north central cancer treatment group N9831 adjuvant trastuzumab trial. J Clin Oncol. 2015;33:701–708.
   PubMedGoogle Scholar
• Stagg J, Loi S, Divisekera U, et al. Anti–ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti–PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci U S A. 2011;108:7142–7147.
   PubMed Web of Science ®Google Scholar
• Dirix LY, Takacs I, Jerusalem G, et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN solid tumor study. Breast Cancer Res Treat. 2018;167:671–686.
   PubMed Web of Science ®Google Scholar
• Chia SKL, Bedard PL, Hilton J, et al. A phase I study of a PD-L1 antibody (Durvalumab) in combination with trastuzumab in HER-2 positive metastatic breast cancer progressing on prior anti HER-2 therapies (CCTGIND.229) [NCT02649686]. J Clin Oncol. 2018;36(15_suppl):1029.
   Web of Science ®Google Scholar
• Loi S, Giobbie-Hurder A, Gombos A, et al. Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial. Lancet Oncol. 2019;20:371–382.
   PubMed Web of Science ®Google Scholar
• Emens LA, Esteva F, Beresford M, et al. Results from KATE2, a randomized phase II study of atezolizumab + trastuzumab emtansine (T-DM1) vs placebo + T-DM1 in previously treated her2+ advanced breast cancer. Poster PD3-01, SABCS 2017, San Antonio, Texas, USA
   Google Scholar
• Kontermann RE, Brinkmann U. Bispecific antibodies. Drug Discov Today. 2015;20:838–847.
   PubMed Web of Science ®Google Scholar
• de Vries Schultink AHM, Doornbos RP, Bakker ABH, et al. Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose. Invest New Drugs. 2018;36:1006–1015.
   PubMed Web of Science ®Google Scholar
• Alsina M, Boni V, Schellens JHM, et al. First-in-human phase 1/2 study of MCLA-128, a full length IgG1 bispecific antibody targeting HER2 and HER3: Final phase 1 data and preliminary activity in HER2+ metastatic breast cancer. J Clin Oncol. 2017;35(15_suppl):2522.
   Google Scholar
• Meric-Bernstam F, Beeram M, Mayordomo JI, et al. Single agent activity of ZW25, a HER2-targeted bispecific antibody, in heavily pretreated HER2-expressing cancers. J Clin Oncol. 2018;36(15_suppl):2500.
   Web of Science ®Google Scholar
• Wermke M, Alt J, Kauh JS, et al. Preliminary biomarker and pharmacodynamic data from a phase I study of single-agent bispecific antibody T-cell engager GBR 1302 in subjects with HER2-positive cancers. J Clin Oncol. 2018;36(5_suppl):69.
   Web of Science ®Google Scholar
• Wermke M, Alt J, Kauh J, et al. Preliminary results from a phase I study of GBR 1302, a bispecific antibody T-cell engager, in HER2 positive cancers. Ann Oncol. 2018;29(suppl_8):1147P.
   Google Scholar
• Kiewe P, Hasmüller S, Kahlert S, et al. Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer. Clin Cancer Res. 2006;12:3085–3091.
   PubMed Web of Science ®Google Scholar
• Haense N, Atmaca A, Pauligk C, et al. A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors. BMC Cancer. 2016;16:420.
   PubMed Web of Science ®Google Scholar
• McDonagh CF, Huhalov A, Harms BD, et al. Antitumor activity of a novel bispecific antibody that targets the Erbb2/Erbb3 oncogenic unit and inhibits heregulin-induced activation of Erbb3. Mol Cancer Ther. 2012;11:582–593.
   PubMed Web of Science ®Google Scholar
• Denlinger CS, Alsina Maqueda M, Watkins DJ, et al. Randomized phase 2 study of paclitaxel (PTX), trastuzumab (T) with or without MM-111 in HER2 expressing gastroesophageal cancers (GEC). J Clin Oncol. 2016;34(15_suppl):4043.
   Web of Science ®Google Scholar
• Plückthun A. designed ankyrin repeat proteins (DARPins): binding proteins for research, diagnostics, and therapy. Annu Rev Pharmacol Toxicol. 2015;55:489–511.
   PubMed Web of Science ®Google Scholar
• Baird R, Omlin A, Kiemle-Kallee J, et al. MP0274-CP101: A phase 1, first-in-human, single-arm, multi-center, open-label, dose escalation study to assess safety, tolerability, and pharmacokinetics of MP0274 in patients with advanced HER2-positive solid tumors. Cancer Res. 2018;78(4 Suppl):OT1-03-02.
   PubMed Web of Science ®Google Scholar
• Pernas S, Tolaney SM. HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance. Ther Adv Med Oncol. 2019;11:1758835919833519.
   Web of Science ®Google Scholar
• Hurvitz SA, Andre F, Jiang Z, et al. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. Lancet Oncol. 2015;16:816–829.
   PubMed Web of Science ®Google Scholar
• André F, O’Regan R, Ozguroglu M, et al. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2014;15:580–591.
   PubMed Web of Science ®Google Scholar
• Pistilli B, Pluard T, Urruticoechea A, et al. Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy. Breast Cancer Res Treat. 2018;168:357–364.
   PubMed Web of Science ®Google Scholar
• Saura C, Bendell J, Jerusalem G, et al. Phase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzumab-based therapy. Clin Cancer Res. 2014;20:1935–1945.
   PubMed Web of Science ®Google Scholar
• Guerin M, Rezai K, Isambert N, et al. PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer. Eur J Cancer. 2017;86:28–36.
   PubMed Web of Science ®Google Scholar
• Baselga J, Im SA, Iwata H, et al. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18:904–916.
   PubMed Web of Science ®Google Scholar
• Di Leo A, Johnston S, Lee KS, et al. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2018;19:87–100.
   PubMed Web of Science ®Google Scholar
• Tolaney S, Burris H, Gartner E, et al. Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2015;149:151–161.
   PubMed Web of Science ®Google Scholar
• Jain S, Shah AN, Santa-Maria CA, et al. Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy. Breast Cancer Res Treat. 2018;171:371–381.
   PubMed Web of Science ®Google Scholar
• Shah PD, Chandarlapaty S, Dickler MN, et al. Phase I study of LJM716, BYL719, and trastuzumab in patients (pts) with HER2-amplified (HER2+) metastatic breast cancer (MBC). J Clin Oncol. 2015;33(15_suppl):590.
   Web of Science ®Google Scholar
• Hudis C, Swanton C, Janjigian YY, et al. A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors. Breast Cancer Res. 2013;15:R110.
   PubMed Web of Science ®Google Scholar
• Goel S, Wang Q, Watt AC, et al. Overcoming therapeutic resistance in HER2-positive breast cancers with CDK4/6 inhibitors. Cancer Cell. 2016;29:255–269.
   PubMed Web of Science ®Google Scholar
• Trapani D, Esposito A, Criscitiello C, et al. Entinostat for the treatment of breast cancer. Expert Opin Investig Drugs. 2017;26:965–971.
   PubMed Web of Science ®Google Scholar
• Lim B, Murthy RK, Jackson S, et al. Open-label phase Ib study of entinostat (E), and lapatinib (L) alone, and in combination with trastuzumab (T) in patients (pts) with HER2+ metastatic (mHER2+) breast cancer after progression on trastuzumab. J Clin Oncol. 2016;34(15_suppl):609.
   Web of Science ®Google Scholar
• Wildiers H, Tryfonidis K, Dal Lago L, et al. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111–10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group. Lancet Oncol. 2018;19:323–336.
   PubMed Web of Science ®Google Scholar
• Rimawi M, Ferrero JM, de la Haba-Rodriguez J, et al. First-line trastuzumab plus an aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor receptor 2-positive and hormone receptor-positive metastatic or locally advanced breast cancer (PERTAIN): a randomized, open-label phase II trial. J Clin Oncol. 2018;36:2826–2835.
   PubMed Web of Science ®Google Scholar
• Tolaney SM, Barry W, Guo H, et al. Immune profile of small HER2+ tumors in the APT trial. Cancer Res. 2018;78(4 Suppl):PD3–01.
   Web of Science ®Google Scholar
• Llombart-Cussac A, Cortés J, Paré L, et al. HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial. Lancet Oncol. 2017;18:545–554.
   PubMed Web of Science ®Google Scholar
• Johnston SRD, Hegg R, Im SA, et al. Phase III, randomized study of dual human epidermal growth factor receptor 2 (HER2) blockade with lapatinib plus trastuzumab in combination with an aromatase inhibitor in postmenopausal women with her2-positive, hormone receptor-positive metastatic breast cancer: ALTERNATIVE. J Clin Oncol. 2018;36:741–748.
   PubMed Web of Science ®Google Scholar
• Modi S, Tsurutani J, Tamura K, et al. Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-low expressing breast cancer: Updated results of a large phase 1 study. Cancer Res. 2019;79(4Suppl):P6-17-02.
   Google Scholar
• Mittendorf EA, Clifton GT, Holmes JP, et al. Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients. Ann Oncol. 2014;25:1735–1742.
   PubMed Web of Science ®Google Scholar
• Peoples GE, Gurney JM, Hueman MT, et al. Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients. J Clin Oncol. 2005;23:7536–7545.
   PubMed Web of Science ®Google Scholar
• Durkee BY, Qian Y, Pollom EL, et al. of pertuzumab in human epidermal growth factor receptor 2–positive metastatic breast cancer. J Clin Oncol. 2016;34:902–909.
   PubMed Web of Science ®Google Scholar
• Le QA, Bae YH, Kang JH. Cost-effectiveness analysis of trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2): positive advanced breast cancer. Breast Cancer Res Treat. 2016;159:565–573.
   PubMed Web of Science ®Google Scholar
• Diaby V, Adunlin G, Ali AA, et al. Cost-effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positive metastatic breast cancer in the United States. Breast Cancer Res Treat. 2016;160:187–196.
   PubMed Web of Science ®Google Scholar
• Gingras I, Gebhart G, de Azambuja E, et al. HER2-positive breast cancer is lost in translation: time for patient-centered research. Nat Rev Clin Oncol. 2017;14:669–681.
   PubMed Web of Science ®Google Scholar
• Baselga J, Lewis Phillips GD, Verma S, et al. between tumor biomarkers and efficacy in EMILIA, a phase III study of trastuzumab emtansine in HER2-positive metastatic breast cancer. Clin Cancer Res. 2016;22:3755–3763.
   PubMed Web of Science ®Google Scholar
• Baselga J, Cortés J, Im SA, et al. analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. J Clin Oncol. 2014;32:3753–3761.
   PubMed Web of Science ®Google Scholar
• Kim SB, Wildiers H, Krop IE, et al. Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) vs. treatment of physician’s choice in previously treated HER2-positive advanced breast cancer: biomarker analyses in TH3RESA. Int J Cancer. 2016;139:2336–2342.
   PubMed Web of Science ®Google Scholar
• Schlange T, Pantel K. Potential of circulating tumor cells as blood-based biomarkers in cancer liquid biopsy. Pharmacogenomics. 2016;17:183–186.
   PubMed Web of Science ®Google Scholar
• Sandstrom M, Lindskog K, Velikyan I, et al. Biodistribution and radiation dosimetry of the anti-HER2 affibody molecule 68Ga-ABY-025 in breast cancer patients. J Nucl Med. 2016;57:867–871.
   PubMed Web of Science ®Google Scholar
• Deri MA, Zeglis BM, Francesconi LC, et al. PET imaging with 89Zr: from radiochemistry to the clinic. Nucl Med Biol. 2013;40:3–14.
   PubMed Web of Science ®Google Scholar
• Gebhart G, Lamberts LE, Wimana Z, et al. Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the Z the ZEPHIR trial. Ann Oncol. 2016;27:619–624.
   PubMed Web of Science ®Google Scholar